Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Tango Therapeutics Inc. — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $90.39 (market cap $41.29B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 11× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Tango Therapeutics Inc. for 0 Days on average.
| IEF | TNGX | |
|---|---|---|
Market Cap | $41.29B | $3.74B |
Volume | 11,588,563 | 3,438,781 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $32.90 |
52-Week Low | $88.92 | $7.50 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.71, up 0.31% with a bearish technical signal from moving averages and oscillators. The ETF shows flat support/resistance around $89-90. Recent dividend payments of $0.31-$0.33 provide income, but financial ratios are unavailable. Market sentiment reflects Treasury volatility amid rising yields and inflation concerns.
Outlook remains cautious due to persistent bond market pressures and macroeconomic uncertainty. Opportunities exist for income-focused investors via dividends, but risks include prolonged yield increases and geopolitical factors affecting fixed income. Monitor Federal Reserve policy shifts for directional cues.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
